-
P210 Efficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 primary outcome results2020 Lara D. Veeken conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access
David Walker, Bernard G Combe, Alan J. Kivitiz, Yoshiya Tanaka, Désirée M F M van der Heijde, Franziska G. Matzkies, +10 more
1citations -
P083 How are beliefs about osteoporosis medicines elicited and addressed in clinical consultations: a video observational study2023 Lara D. Veeken conference-abstract Health Professions Patient-Provider Communication in Healthcare Open access
Ashley Hawarden, Laurna Bullock, Montserrat León‐García, Sandra A. Hartasanchez, Ian G Hargraves, Rob Horne, +4 more
1citations -
P163 Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials2024 Lara D. Veeken conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access
Martín Rudwaleit, Matthew Brown, Floris Alexander van Gaalen, Nigil Haroon, Lianne S. Gensler, Carmen Fleurinck, +8 more
1citations -
OA16 Bimekizumab treatment resulted in improvements in MRI inflammatory and structural lesions in the sacroiliac joints of patients with axial spondyloarthritis: 52-week results and post hoc analyses from two Phase 3 studies2025 Lara D. Veeken conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access
Walter P. Maksymowych, Sofía Ramiro, Denis Poddubnyy, Xenofon Baraliakos, Robert George William Lambert, Ute Massow, +4 more
1citations -
P217 Efficacy and safety of filgotinib for patients with RA naïve to MTX therapy: FINCH3 primary outcome results2020 Lara D. Veeken conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access
Neil D McKay, Désirée M F M van der Heijde, René Westhovens, William F. C. Rigby, D. W. T. CHING, Beatrix Bartók, +10 more
0citations -
P133 Filgotinib in patients with RA with inadequate response to methotrexate: FINCH 1 52-week efficacy and patient reported outcomes data2021 Lara D. Veeken conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access
David Walker, Alan Kivitz, Yoshiya Tanaka, Susan Lee, Lei Ye, Hao Hu, +17 more
0citations -
P271 To what extent are baseline characteristics in biologic-experienced patients with psoriatic arthritis associated with achievement of minimal disease activity at week 24 of guselkumab treatment: a post hoc analysis of the phase IIIb COSMOS clinical trial
William L. Tillett, Sarah Ohrndorf, Julio A. Ramírez, Marlies Neuhold, Robert Wapenaar, Elke Theander, +4 more
0citations -
E089 Effect of secukinumab on radiographic progression and inflammation in sacroiliac joints and spine in patients with non-radiographic axial spondyloarthritis: 2-year imaging outcomes from a Phase III randomised trial
Helena Marzo‐Ortega, Jürgen Braun, Ricardo Blanco, Lianne S. Gensler, Filip E Van den Bosch, Stephen Hall, +7 more
0citations -
P187 Safety and efficacy of ixekizumab treatment in patients with axial spondyloarthritis: 3-year results from the COAST programme2023 Lara D. Veeken conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access
Atul A. Deodhar, Denis Poddubnyy, Proton Rahman, Rebecca J. Bolce, Soyi Liu Leage, Andris Kronbergs, +2 more
0citations -
P191 Efficacy and improvement in patient-reported outcomes at weeks 16 and 52 in ixekizumab treated biological naïve patients with radiographic axial spondyloarthritis achieving clinically important pain at night reduction at week 16: results from COAST-V trial
Sofía Ramiro, Cédric Lukas, Michael John Nissen, Yves Schymura, Khai Jing Ng, Gabriel Doridot, +3 more
0citations